Alan Connaughton

Genentech, Inc. develops, manufactures and markets pharmaceutical products for life-threatening medical conditions. It studies various areas including oncology, immunology, neuroscience, ophthalmic diseases, microbial pathogenesis, metabolic diseases, cardiovascular diseases, and opportunistic areas. The company was founded by Herb W. Boyer and Robert A. Swanson in 1976 and is headquartered in South San Francisco, CA.

Oldtech, Inc. was engaged in developing treatments for conditions that affect the back of the eye, including age related macular degeneration (AMD) and diabetic macular edema (DME). The company was headquartered in New York.

North Run Capital LP (NRC) is an independent hedge fund management firm headquartered in Boston, Massachusetts. The firm was founded by Todd Hammer and Thomas Ellis in 2002. NRC provides investment advisory services to high net-worth clients.

AMO Development LLC designs, develops and manufactures femtosecond laser technology for use in ophthalmology. It offers Keratoplasty a blade-free laser approach used to incise corneal tissue. The firm's products include metal cone and glass lens for disposable patient interface. The company was founded in 1997 and is headquartered in Irvine, CA.

AcuFocus, Inc. develops KAMRA inlay for the treatment of presbyopia. Its KAMRA inlay is an intra-corneal inlay designed to create a small aperture effect, allowing the eye to see near and intermediate objects more clearly. The company was founded in 2001 and is headquartered in Irvine, CA.

TrueVision Systems, Inc. provides 3D vision systems for microscopes. It offers pre-operative image registration, intra-operative eye tracking, incision location calculator, surgeon incision preferences and default settings, Phaco SIA compensator, and 3D overlay depth control. The company was founded by Michael A. Weissman on October 14, 2003 and is headquartered in Goleta, CA.

WaveTec Vision Systems, Inc. develops and provides wavefront measurement technologies. It focuses on research, development, manufacturing, and distribution of the Optiwave Refractive Analysis (ORA) system with VerifEye used during cataract surgery. The firm offers ophthalmic medical devices. The company was founded by Kenneth C. Aldrich, William B. Adams, Thomas J. Berryman, and Tony Van Heugten in 1997 and is headquartered in Aliso Viejo, CA.

DOSE Medical Corp. engages in the provision of investment services. The company is headquartered in San Clemente, CA.

ForSight VISION5, Inc. develops ocular drug delivery technologies and device solutions for ophthalmic diseases. It engages in the development of non-invasive products to replace eye drops and provide sustained therapy for major anterior segment eye diseases including glaucoma, dry eye, and allergy. Its lead product candidate is the Helios insert, a novel, non-invasive delivery system designed to allow glaucoma and ocular hypertensive patients to continually receive their medication. The company was founded by Eugene de Juan Jr., J. Andrew Corley and K. Angela Macfarlane in 2010 and is headquartered in Madison, NJ.

Oculeve, Inc. develops devices for dry eye disease treatment. The company was founded by D. Michael Ackermann, Brandon M. Felkins, Garrett Cale Smith and Victor Wayne McCray in 2011 and is headquartered in Parsippany, NJ.

Neurotech Pharmaceuticals, Inc. designs and develops therapeutic systems for retinal diseases. The company was founded in 1995 and is headquartered in Cumberland, RI.

Versant Venture Management LLC (Versant Ventures) is an independent venture capital firm founded in 1999 by Brian Atwood, Samuel Colella, Bill Link and Ross Jaffe. The firm is headquartered in San Francisco with additional offices in Basel and Vancouver.

eyeonics, Inc. designs, develops, manufactures and sells premium intraocular lenses. Its lenses are implantable devices that replace the natural lens in the human eye, typically after the natural lens has developed cataracts that can significantly impair vision. The firm's products are designed to both replace a cataractous lens and correct a refractive error. The company was founded by Andrew J. Corley and Stuart J. Cumming in 1998 and is headquartered in Aliso Viejo, CA.

Braille Institute of America, Inc. offers different services to people with vision loss. The company was founded by Robert J. Atkinson in 1919 and is headquartered in Los Angles, CA.

Equinox Ophthalmic, Inc. operates as a biotechnology company. It specializes in cataract, corneal and glaucoma surgery. The company was founded by John Berdahl and is headquartered in Sioux Falls, SD.

Allegro Ophthalmics LLC operates as a biopharmaceutical company. It focuses on the development of novel integrin-regulating therapies for the treatment of ocular diseases. The company was founded by Hampar Karageozian and John Park and is headquartered in San Juan Capistrano, CA.

AEON Biopharma Sub, Inc. is a biopharmaceutical company. It focuses on developing a proprietary botulinum toxin complex, ABP-450, for debilitating medical conditions, with an initial focus on the neurology and gastroenterology markets. The company was founded by Robert E. Grant on February 24, 2012 and is headquartered in Newport Beach, CA.

CorneaGen, Inc. engages in the provision of cornea care services. It offers precision cut corneal tissue, Descemet’s Membrane Endothelial Keratoplasty, and Descemet’s Stripping Automated Endothelial Keratoplasty. The firm's products include EndoSerter, Geuder Glass Cannula, and Donor Trephine Punch. The company was founded in 2016 and is headquartered in Seattle, WA.

RxSight I LLC, a special purpose fund, formed to invest in RxSight, Inc.

Aviana Molecular Technologies LLC develops technologies for point of care diagnostic of infections. It develops a miniaturized biosensor capable of attaching to a smartphone or smart device through Bluetooth or other wireless connections. The company's diagnostic system is a diagnostic platform that can accurately, detect a target infectious disease, biomarkers or proteins in both clinical and scientific research settings. Its platform uses the latest developments in cellular communications, semiconductor electronics, micro-fluidics and manufacturing methods to create a unique point-of-care diagnostic platform to detect biomarkers or infections. The company was founded by Vanaja Ragavan in 2008 and is headquartered in Orlando, FL.

Flying L Management LLC (Flying L Management) is a venture capital firm founded in 2016. The firm is headquartered in Newport beach, California.

TearClear Corp. operates as an early-stage medical science company. It develops a hydrogel filter to remove potentially harmful preservatives from multi dose topical ophthalmic products used to treat chronic diseases such as glaucoma, dry-eye and allergic conjunctivitis. The company was founded by Anuj Chauhan in 2015 and is headquartered in Copley, OH.

Noden Pharma DAC is a pharmaceutical company, which engages in the acquisition of prescription medicines across a range of therapeutic areas. It manufactures, markets, and sells Tekturna and Tekturna HCT, which contain aliskiren, a direct renin inhibitor, for the treatment of hypertension. The company is headquartered in Dublin, Ireland.

Noden Pharma USA, Inc. is engaged in manufacturing and commercialization of filled and finished medicine products. The company is headquartered in Orlando, FL.

Vialase, Inc. provides healthcare services. The company is headquartered in Aliso Viejo, CA.

Neurolens, Inc. is a company that commercializes breakthrough technology to improve vision care. The company's patented contoured prism technology provides visual comfort for the nearly 65% of US adults who complain of headaches, neck/shoulder pain, and eyestrain when using digital devices, reading, or doing detail work. The company is based in Coppell, TX. Inspired by a breakthrough discovery linking optometry and neurology, Neurolens is unlocking a new dimension of vision care. The Neurolens contoured prism design helps the eyes work together comfortably, bringing the eyes into alignment to relieve painful symptoms. The technology is only available to independent eye care providers. The company was founded in 2012 by Davis Corley, and Pierre Bertrand has been the CEO of the company since 2019.

Aurion Biotech, Inc. is a clinical-stage biotech company with offices in multiple locations. Aurion Biotech has initiated clinical trials in the US in 2023. The company is based in Seattle, WA. The company's mission is to restore vision to millions of patients with life-changing regenerative therapies. Aurion Biotech has received the prestigious Prix Galien award for best start-up in biotech. The company's first candidate is an off-the-shelf, clinically validated cell therapy for corneal care, which has received regulatory approval. The company is privately held and backed by leading investors, including Deerfield, Alcon, Petrichor, Flying L Partners, Falcon Vision/KKR, and Visionary Ventures. Greg Kunst has been the CEO of the company since 2021.